R
Robert R. Henry
Researcher at University of California, San Diego
Publications - 327
Citations - 34604
Robert R. Henry is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Insulin & Diabetes mellitus. The author has an hindex of 89, co-authored 323 publications receiving 31658 citations. Previous affiliations of Robert R. Henry include University of Arizona & University of Arkansas for Medical Sciences.
Papers
More filters
Journal ArticleDOI
Type 2 diabetes mellitus.
Ralph A. DeFronzo,Ele Ferrannini,Leif Groop,Robert R. Henry,William H. Herman,Jens J. Holst,Frank B. Hu,C. Ronald Kahn,Itamar Raz,Gerald I. Shulman,Donald C. Simonson,Marcia A. Testa,Ram Weiss +12 more
TL;DR: The greatest need is for agents that enhance insulin sensitivity, halt the progressive pancreatic β-cell failure that is characteristic of T2DM and prevent or reverse the microvascular complications.
Journal ArticleDOI
Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes
TL;DR: Exenatide significantly reduced HbA(1c) in patients with type 2 diabetes failing maximally effective doses of a sulfonylurea as monotherapy and was associated with weight loss.
Journal ArticleDOI
Retinol-Binding Protein 4 and Insulin Resistance in Lean, Obese, and Diabetic Subjects
Timothy E. Graham,Qin Yang,Matthias Blüher,Ann Hammarstedt,Theodore P. Ciaraldi,Robert R. Henry,Christopher J. Wason,Andreas Oberbach,Per-Anders Jansson,Ulf Smith,Barbara B. Kahn +10 more
TL;DR: RBP4 is an adipocyte-secreted molecule that is elevated in the serum before the development of frank diabetes and appears to identify insulin resistance and associated cardiovascular risk factors in subjects with varied clinical presentations, providing a rationale for antidiabetic therapies aimed at lowering serum RBP4 levels.
Journal ArticleDOI
Impaired fasting glucose and impaired glucose tolerance: implications for care.
David M. Nathan,Mayer B. Davidson,Ralph A. DeFronzo,Robert J. Heine,Robert R. Henry,Richard E. Pratley,Bernard Zinman +6 more
TL;DR: With the development of diabetes, there is a large increase in risk for CVD, as well as for long-term complications affecting the eyes, kidneys, and nervous system, and the risk of a CVD event is modestly increased.
Journal ArticleDOI
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
Alan M. Garber,Robert R. Henry,Robert E. Ratner,Pedro A Garcia-Hernandez,Hiromi Rodriguez-Pattzi,Israel Olvera-Alvarez,Paula M Hale,Milan Zdravkovic,Bruce W. Bode +8 more
TL;DR: Liraglutide is safe and effective as initial pharmacological therapy for type 2 diabetes mellitus and leads to greater reductions in HbA(1c), weight, hypoglycaemia, and blood pressure than does glimepiride.